Cambridge, United Kingdom

Carlos Fenandez Lence


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Carlos Fenandez Lence in Phthalazinone Derivatives

Introduction

Carlos Fenandez Lence is a notable inventor based in Cambridge, GB. With a focus on medicinal chemistry, he has contributed significantly to the field with his innovative work, particularly in the development of phthalazinone derivatives. His work embodies the spirit of innovation and the relentless pursuit of new solutions in pharmaceutical research.

Latest Patents

Carlos holds a patent for phthalazinone derivatives. The patent describes a compound represented by a particular formula, indicating that A and B can form an optionally substituted, fused aromatic ring. The patent further specifies that X and Y can be various combinations of chemical groups, showcasing a complex structure that allows for significant versatility in its applications. This invention is indicative of the advancements being made in drug development.

Career Highlights

Carlos is currently associated with AstraZeneca AB, a leading global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. His role at AstraZeneca highlights his commitment to advancing medical science through innovative research and development.

Collaborations

Throughout his career, Carlos has collaborated with esteemed colleagues, including Keith Allan Menear and Muhammad Hashim Javaid. These collaborations have likely contributed to the synergistic approach in their research, fostering innovation and enhancing the overall impact of their work.

Conclusion

Carlos Fenandez Lence's contributions to the field of medicinal chemistry through his patent on phthalazinone derivatives represent a substantial step forward in pharmaceutical innovations. His work at AstraZeneca underscores the importance of research collaborations in driving the development of new and effective therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…